Apellis(US:APLS) Financial Modeling Prep·2026-02-23 18:00Core Viewpoint - Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science, developing innovative therapies for serious diseases, with two approved C3-targeting medicines [1] Financial Performance - Apellis is set to release its quarterly earnings on February 24, 2026, with Wall Street estimating an earnings per share (EPS) of -$0.39 and analysts predicting a slightly larger loss of -$0.41 per share [2][6] - Revenue projections are estimated at $199.4 million by Wall Street and $199 million by analysts [2] - The current stock price is $22.28, reflecting a 2.3% decrease, with a market capitalization of $2.82 billion and a price-to-earnings (P/E) ratio of 71.87 [3][6] Stock Performance - Over the past year, APLS stock has fluctuated between a low of $16.10 and a high of $30.48 [3] - The fifty-day simple moving average is $23.31, while the two-hundred-day simple moving average is $23.87 [3] Financial Ratios - The company maintains a quick ratio of 3.10 and a current ratio of 3.54, indicating strong liquidity [4][6] - The debt-to-equity ratio is 0.90, showing moderate financial leverage [4][6] - The price-to-sales ratio is 2.77, and the enterprise value to sales ratio is also 2.77, reflecting its market value compared to sales [4] Market Expectations - The upcoming earnings report is crucial for APLS as it could influence the stock's near-term price movement, with potential upward trends if results exceed expectations [5] - The sustainability of any immediate price changes will depend on management's discussion during the earnings call [5]